Danaher (NYSE:DHR) Releases FY19 Earnings Guidance

Danaher (NYSE:DHR) updated its FY19 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $4.75-4.80 for the period, compared to the Thomson Reuters consensus estimate of $4.85. Danaher also updated its FY 2019 guidance to $4.75-4.80 EPS.

Several research firms have recently commented on DHR. Wolfe Research began coverage on shares of Waters in a research note on Thursday, May 30th. They set an underperform rating for the company. Zacks Investment Research downgraded shares of GALP ENERGIA SG/ADR from a hold rating to a sell rating in a research note on Monday, May 6th. Janney Montgomery Scott lifted their price objective on shares of Danaher from $136.00 to $174.00 and gave the stock a buy rating in a research note on Wednesday, April 17th. Needham & Company LLC reiterated a buy rating and set a $155.00 price objective (up from $142.00) on shares of Danaher in a research note on Friday. Finally, Piper Jaffray Companies upgraded shares of Post from a neutral rating to an overweight rating and lifted their price objective for the stock from $106.00 to $130.00 in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $139.08.

Shares of NYSE:DHR traded down $1.39 on Friday, hitting $141.61. 3,821,795 shares of the company were exchanged, compared to its average volume of 2,343,584. Danaher has a 1-year low of $94.59 and a 1-year high of $145.50. The stock has a 50 day moving average price of $140.27. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.18 and a quick ratio of 1.74. The stock has a market cap of $102.38 billion, a price-to-earnings ratio of 31.33, a P/E/G ratio of 2.58 and a beta of 0.96.

Danaher (NYSE:DHR) last posted its earnings results on Thursday, July 18th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.15 by $0.04. The company had revenue of $5.16 billion during the quarter, compared to the consensus estimate of $5.09 billion. Danaher had a net margin of 12.22% and a return on equity of 11.73%. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.15 earnings per share. On average, sell-side analysts forecast that Danaher will post 4.78 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.17 per share. The ex-dividend date is Thursday, June 27th. This represents a $0.68 dividend on an annualized basis and a yield of 0.48%. Danaher’s dividend payout ratio is presently 15.04%.

In related news, Director Donald J. Ehrlich sold 5,000 shares of the business’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $132.95, for a total transaction of $664,750.00. Following the completion of the transaction, the director now directly owns 100,603 shares in the company, valued at $13,375,168.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP William King sold 12,950 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $129.92, for a total transaction of $1,682,464.00. Following the transaction, the senior vice president now owns 29,070 shares of the company’s stock, valued at $3,776,774.40. The disclosure for this sale can be found here. Insiders have sold 453,448 shares of company stock valued at $59,724,640 over the last 90 days. 11.40% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.

Read More: FAANG Stocks

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.